Cargando…
RNAi-mediated rheostat for dynamic control of AAV-delivered transgenes
Adeno-associated virus (AAV)-based gene therapy could be facilitated by the development of molecular switches to control the magnitude and timing of expression of therapeutic transgenes. RNA interference (RNAi)-based approaches hold unique potential as a clinically proven modality to pharmacological...
Autores principales: | Subramanian, Megha, McIninch, James, Zlatev, Ivan, Schlegel, Mark K., Kaittanis, Charalambos, Nguyen, Tuyen, Agarwal, Saket, Racie, Timothy, Alvarado, Martha Arbaiza, Wassarman, Kelly, Collins, Thomas S., Chickering, Tyler, Brown, Christopher R., Schmidt, Karyn, Castoreno, Adam B., Shulga-Morskaya, Svetlana, Stamenova, Elena, Buckowing, Kira, Berman, Daniel, Barry, Joseph D., Bisbe, Anna, Maier, Martin A., Fitzgerald, Kevin, Jadhav, Vasant |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10082758/ https://www.ncbi.nlm.nih.gov/pubmed/37031257 http://dx.doi.org/10.1038/s41467-023-37774-5 |
Ejemplares similares
-
Selection of GalNAc-conjugated siRNAs with limited off-target-driven rat hepatotoxicity
por: Janas, Maja M., et al.
Publicado: (2018) -
An investigational RNAi therapeutic targeting Factor XII (ALN-F12) for the treatment of hereditary angioedema
por: Liu, Jingxuan, et al.
Publicado: (2019) -
Small circular interfering RNAs (sciRNAs) as a potent therapeutic platform for gene-silencing
por: Jahns, Hartmut, et al.
Publicado: (2021) -
Chimeric siRNAs with chemically modified pentofuranose and hexopyranose nucleotides: altritol-nucleotide (ANA) containing GalNAc–siRNA conjugates: in vitro and in vivo RNAi activity and resistance to 5′-exonuclease
por: Kumar, Pawan, et al.
Publicado: (2020) -
Investigating the pharmacodynamic durability of GalNAc–siRNA conjugates
por: Brown, Christopher R, et al.
Publicado: (2020)